

REQ-2023-098 Supplementary material

Table 1S. Distribution of MIC values of cefiderocol and comparators in meropenem susceptible and resistant Enterobacterales using EUCAST breakpoints

Enterobacterales (220)	MEROPENEM	MIC (mg/L)											% Resistance
		≤0.03	0.06 or ≤0.06	0.12 or ≤0.12	0.25	0.5	1	2	4	8 or >4	16 or >8	>16 or 32	
CFDC	MEM-R (34)	1	5	3	10	1	5	6	2	1			8.8%
	MEM-S (186)	33	21	19	35	26	18	25	9	0			4.8%
FEP	MEM-R (34)			0	0	0	0	0	1	4	3	26	97%
	MEM-S (186)			57	9	4	4	5	11	7	21	68	51%
CZA	MEM-R (34)			13	0	0	1	3	1	<u>7</u>	2	7	26.5%
	MEM-S (186)			138	15	12	5	0	2	2	1	11	6.4%
C/T	MEM-R (34)			0	0	4	3	3	0	1	1	22	70%
	MEM-S (186)			32	34	20	14	13	6	7	17	43	36%
MEV	MEM-R (34)		7	1	0	1	2	1	1	<u>2</u>	7	12	55.8%
	MEM-S (186)		107	4	8	18	23	14	4	8			0%
IMR	MEM-R (34)			6	2	1	6	3	2	4	2	8	47%
	MEM-S (186)	1	6	72	24	19	24	17	4	10	5	4	12.3%
AZA	MEM-R (34)			13	0	2	6	<u>1</u>	0	1	1	10	-
	MEM-S (186)			135	18	15	6	4	0	1	1	6	--
CIP	MEM-R (34)		0	1	1	3	2	0	2	3	22		94%
	MEM-S (186)		54	12	5	5	1	9	2	4	94		61%
TGC	MEM-R (34)				2	3	12	4	<u>3</u>	10			85%
	MEM-S (186)			26	38	42	34	25	16	5			43%
CST	MEM-R (34)			3	10	9	3	0	1	1	7		26%
	MEM-S (186)			22	76	54	7	2	0	3	22		13%

Cefiderocol (CFDC), Cefepime (FEP), Ceftazidime-avibactam (CZA), Ceftolozane-tazobactam (C/T), Meropenem (MEM), Meropenem-vaborbactam (MEV), Imipenem-relebactam (IMR), Aztreonam-avibactam (AZA), Ciprofloxacin (CIP), Tigecycline (TGC), Colistin (CST), MEN-S: meropenem susceptible, MEN-R: meropenem resistant

Table 2S. Distribution of MIC values of cefiderocol and comparators in meropenem susceptible and resistant *P.aeruginosa* using EUCAST breakpoints

<i>P. aeruginosa</i> (159)	MEROPENEM	MIC (mg/L)											% Resistance
		≤0.03	0.06 or ≤0.06	0.12 or ≤0.12	0.25 or ≤0.25	0.5	1	2 or ≤2	4	8 or >4	16 or >8	>16 or 32	
CFDC	MEM-R (58)	3	12	17	19	3	2	2					0%
	MEM-S (101)	13	34	23	15	6	2	7	1				1%
FEP	MEM-R (58)								2	11	21	24	77.5%
	MEM-S (101)				2	2	11	24	17	13	21	11	31.6%
CZA	MEM-R (58)						2	1	11	28	8	14	37.9%
	MEM-S (101)			7	2	3	5	29	32	15	2	6	7.9%
C/T	MEM-R (58)					9	11	12	0	7	0	19	44.8%
	MEM-S (101)			3	19	33	20	9	1	1	2	13	15.8%
MEV	MEM-R (58)						1	0	1	6	27	23	86%
	MEM-S (101)		5	8	15	10	18	17	4	23	1		1%
IMR	MEM-R (58)						16	15	5	1	4	17	46%
	MEM-S (101)	3	0	8	26	28	24	3	1	3	3	3	10%
AZA	MEM-R (58)					1	0	0	0	0	12	45	-
	MEM-S (101)			5	3	2	3	2	1	7	30	48	-
CIP	MEM-R (58)			1	2	7	6	3	2	2	35		94.8%
	MEM-S (101)		17	22	13	4	3	11	1	3	27		48.5%
TGC	MEM-R (58)					1	0	1	6	50			-
	MEM-S (101)			2	1	0	8	5	25	60			-
CST	MEM-R (58)			2	12	31	10	0	0	1	2		5.1%

	MEM-S (101)			5	27	46	17	3	1	1	1		3%
--	-------------	--	--	---	----	----	----	---	---	---	---	--	----

Cefiderocol (CFDC), Cefepime (FEP), Ceftazidime-avibactam (CZA), Ceftolozane-tazobactam (C/T), Meropenem (MEM), Meropenem-vaborbactam (MEV), Imipenem-relebactam (IMR), Aztreonam-avibactam (AZA), Ciprofloxacin (CIP), Tigecycline (TGC), Colistin (CST); MEN-S: meropenem susceptible, MEN-R: meropenem resistant